Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.005 AUD | -16.67% | -16.67% | -28.57% |
04-29 | Alterity Therapeutics Limited Presents New Data Demonstrating Potential of ATH434 to Treat Rare Neurodegenerative Diseases | CI |
04-16 | ADRs End Lower, Purple Biotech Ltd. Declines 29% | DJ |
Business Summary
Managers
Managers | Title | Age | Since |
---|---|---|---|
David Stamler
CEO | Chief Executive Officer | 63 | 30/04/17 |
Geoffrey Kempler
FOU | Founder | 69 | 10/11/97 |
Phillip Hains
DFI | Director of Finance/CFO | 64 | 30/04/14 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Geoffrey Kempler
FOU | Founder | 69 | 10/11/97 |
Peter Marks
BRD | Director/Board Member | 68 | 28/07/05 |
Lawrence Gozlan
BRD | Director/Board Member | 45 | 07/08/11 |
Brian Meltzer
BRD | Director/Board Member | 70 | 08/12/99 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 2,802,360,380 | 2,436,015,074 ( 86.93 %) | 0 | 86.93 % |
Company contact information
Alterity Therapeutics Ltd.
350 Collins Street Level 14
3000, Melbourne
+61 3 9349 4906
http://www.alteritytherapeutics.comSector
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-28.57% | 17.34M | |
+25.69% | 47.9B | |
+46.90% | 41.42B | |
-3.46% | 40.7B | |
-6.20% | 28.92B | |
+9.17% | 25.55B | |
-20.42% | 19.27B | |
+0.17% | 12.15B | |
+28.07% | 12.14B | |
-1.24% | 11.99B |
- Stock Market
- Equities
- ATH Stock
- Company Alterity Therapeutics Limited